首页> 美国卫生研究院文献>Global Health Medicine >Corticosteroid therapy for severe COVID-19 pneumonia: optimal dose and duration of administration
【2h】

Corticosteroid therapy for severe COVID-19 pneumonia: optimal dose and duration of administration

机译:皮质类固醇治疗严重Covid-19肺炎:最佳剂量和给药持续时间

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Severe COVID-19 is associated with a hyperinflammatory state, and corticosteroid therapy may be effective. We review the recent literature and discuss the appropriate dose and duration of corticosteroid therapy. Low-dose corticosteroid therapy is often used to treat COVID-19. However, several doses of methylprednisolone (or prednisolone) have been attempted, ranging from about 40 mg/day to 2 mg/kg/day. Doses may need to be adjusted depending on severity. Corticosteroid therapy is generally administered for a short period over several days. However, COVID-19-induced respiratory failure is often prolonged, so longer administration may be considered. Careful monitoring for complications due to corticosteroid therapy is vital.
机译:严重的Covid-19与高炎症状态有关,皮质类固醇治疗可能是有效的。我们审查了最近的文献,并讨论了皮质类固醇治疗的适当剂量和持续时间。低剂量皮质类固醇治疗通常用于治疗Covid-19。然而,已经尝试了几种剂量的甲基丙酮(或泼尼松龙),范围为约40mg /天至2mg / kg /天。可能需要根据严重程度进行调整剂量。皮质类固醇治疗通常在几天内施用短期。然而,Covid-19诱导的呼吸衰竭通常延长,因此可以考虑延长的给药。仔细监测皮质类固醇治疗导致的并发症是至关重要的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号